Insmed reported preliminary 2025 revenue Friday of $606.4 million, up 67% year over year. Analysts polled by FactSet expect $518 million.
US revenue for the year grew 78% to $453 million, while international sales jumped 41% to $153.5 million, according to Insmed. The company said it will report final Q4 and 2025 financial results in February. Insmed shares were up 10% in recent premarket activity.
Crypto shares jumped in premarket trading. DeFi Tech up over 4%; IREN up 3%; TeraWulf up 2%.